Sulindac | Placebo | ||||||||
---|---|---|---|---|---|---|---|---|---|
Before | After | Before | After | ||||||
bcl-2 | Base | 3 (2–3) | 3 (2–3) | 2.5 (2–3) | 2.5 (2–3) | ||||
Surface | 1 (1–2) | 1 (1–2) | 1.5 (1–2) | 1 (1) | |||||
bax | Base | 2 (2) | 2 (1–2) | 1.5 (1–2) | 1.5 (1–2) | ||||
Surface | 3 (3–4) | 3 (2–4) | 2.5 (2–3) | 2.5 (2–3) | |||||
p21 | Base | 1 (1) | 1 (1) | 1 (1) | 1 (1) | ||||
Surface | 3.5 (2–4) | 3 (3–4) | 3 (3–4) | 3 (3–4) | |||||
p53 | Base | 1 (1) | 1 (1) | 1 (1) | 1 (1) | ||||
Surface | 1 (1) | 1 (1) | 1 (1) | 1 (1) |
p21 was only expressed in the upper third of the crypt and at the luminal surface; no p53 expression was seen. No statistical differences were noted by Wilcoxon paired rank sum test.